National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2 clinical trials · 2 recruiting · NIH
Trials by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
RECRUITINGPhase 2NCT05440422
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) -...
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke....
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Enrolling: 451 location
Systemic Lupus ErythematosusCardiovascular DiseasePremature Atherosclerosis
RECRUITINGNCT05567198
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as...
Background: Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cyclophosphamide (CYC)....
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Enrolling: 1001 location
Systemic Lupus Erythematosus (Sle)Primary Ovarian Insufficiency (Poi)